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Cisplatin anti-tumour potentiation by tirapazamine
results from a hypoxia-dependent cellular sensitization
to cisplatin
MS Kovacs, DJ Hocking, JW Evans, BG Siim*, BG Wouters and JM Brown
Cancer Biology Research Laboratory, GK103, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
Summary Tirapazamine (TPZ) is a new anticancer drug that is activated specifically at the low oxygen level typically found in solid tumours.
It exhibits preferential cytotoxicity towards hypoxic cells and has been shown in preclinical studies with transplanted tumours and in phase II
and III clinical trials to potentiate the anti-tumour efficacy of cisplatin without increasing its systemic toxicity. At present, the mechanism for this
potentiation is unknown. Here we show that there is a schedule-dependent enhancement of cisplatin cytotoxicity by TPZ for cells in vitro that
is similar to that seen with transplanted murine tumours. This cisplatin potentiation depends on the TPZ exposure being at oxygen
concentrations below 1%, which are typical of many cells in tumours but not in normal tissues. Also, the interaction between TPZ and cisplatin
does not occur in cells mutant in ERCC4, a protein essential for repair of DNA interstrand cross-links. Incubation of the cells with TPZ under
hypoxia prior to cisplatin treatment increases cisplatin-induced DNA interstrand cross-links with kinetics suggesting that TPZ inhibits or delays
repair of the DNA cross-links. In conclusion, we show that the tumour-specific potentiation of cisplatin cytotoxicity is likely the result of an
interaction between TPZ and cisplatin at the cellular level that requires the low oxygen levels typical of those in solid tumours. The mechanism
of the interaction appears to be through a potentiation of cisplatin-induced DNA interstrand cross-links, possibly as a result of a diminished or
delayed repair of these lesions
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Article no. bjoc.1998.0492Tirapazamine (3-amino-1,2,4-benzotriazine 1,4-dioxide: SR 4233)
(TPZ) is a new anticancer drug that is activated in hypoxic cells to
a highly damaging free radical (Brown, 1993), resulting in selec-
tive cytotoxicity towards hypoxic cells (Zeman et al, 1986; Brown,
1993). Because of this preferential toxicity to hypoxic cells, TPZ
was originally developed as an adjunct to radiation therapy, since
there is compelling evidence that hypoxic cells in tumours lead to
failure of local control by radiotherapy (Gatenby et al, 1988;
Nordsmark et al, 1996; Brizel et al, 1997). In support of this use,
preclinical experiments have shown that the addition of TPZ to
fractionated irradiation leads to significantly greater tumour cell
kill without enhancing radiation damage to normal tissues (Brown
and Lemmon, 1990, 1991). These studies have led to clinical trials
of TPZ combined with radiotherapy (Lee et al, 1997).
However, in addition to its potentiation of fractionated radia-
tion, TPZ also produces a schedule-dependent enhancement of the
anti-tumour activity of cisplatin and carboplatin in experimental
tumours (Dorie and Brown, 1993, 1997; Durand, 1994; Mangold
et al, 1997; Siemann and Hinchman, 1998). The potentiation of
tumour cell kill by TPZ when added to these platinum-containing
drugs is significant for cancer therapy as the drug does not enhance
the systemic toxicity of either cisplatin or carboplatin (Dorie and
Brown, 1993, 1997; Siemann and Hinchman, 1998). These studies
have led to clinical testing of TPZ combined with cisplatin with a
variety of tumours (Rodriguez et al, 1996; Graham et al, 1997;Received 20 October 1998
Revised 17 December 1998
Accepted 18 December 1998
Correspondence to: JM BrownMiller et al, 1997; Treat et al, 1997). A recently completed phase
III study of TPZ combined with cisplatin for stage IIIB and IV
non-small-cell lung cancer has shown a doubling of overall
response rates and a significant survival advantage compared to
cisplatin alone (von Pawel and von Roemeling, 1998).
Despite these promising preclinical and clinical results, the
mechanism by which TPZ potentiates the anti-tumour effective-
ness of platinum-based anticancer therapies is unknown. An
obvious possibility is that since TPZ selectively kills hypoxic cells
in tumours (Durand, 1994; Kim and Brown, 1994), and these cells
are resistant to killing by cisplatin (Grau and Overgaard, 1988),
there should be complementary cell kill between the two drugs.
Indeed, evidence for such complementarity of cell killing between
cisplatin and TPZ has been obtained with human tumour
xenografts by Durand (1994). However, this cannot account for all
of the activity, since we have obtained preliminary data that
pretreatment of hypoxic cells in vitro can sensitize them to a
subsequent cell killing by cisplatin (Dorie and Brown, 1993).
Also, Durand has demonstrated in a xenograft model that the
combined killing of TPZ plus cisplatin is greater than that
predicted on the basis of additive cytotoxicities (Durand, 1994).
Of particular interest in the latter data is that potentiation of
cisplatin toxicity occurred even in the cells closest to blood
vessels, suggesting that more than the hypoxic cells might be
sensitized to cisplatin by TPZ. However, this is not consistent with
the conclusion from other studies that the damaging species from
TPZ is a radical with a very short, subcellular diffusion distance
(Brown, 1993; Evans et al, 1998).1245
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Figure 1 Effect on clonogenic survival of combining a 1-h exposure to TPZ
(20 m M) under hypoxia with a 1-h exposure to cisplatin (20 m M) on mouse NIH
3T3 cells or human LXFL 529 non-small-cell lung cancer cells. The two drugs
were given either at the same time (0 h between TPZ and cisplatin) or the
cisplatin exposure was given at varying times after the TPZ exposure. Pooled
data from two experiments for each cell line (means and s.e.m.)The present studies were therefore undertaken to explore in
more depth the nature of the interaction between TPZ and
cisplatin, to examine its oxygen dependence, and to attempt to
determine the mechanism for the interaction. We show that much,
if not all, of the potentiation of the antitumour effects in vivo can
be explained by a cellular interaction that depends on TPZ metab-
olism under hypoxia. Further, the potentiation is associated with
an increase in DNA interstrand cross-links following cisplatin
exposure that may be related to an inhibition of, or delay in, the
repair of these lesions.
MATERIALS AND METHODS
Cell lines
Cell lines were maintained as monolayer cultures in vitro in a
humidified atmosphere of 95% air and 5% carbon dioxide at 37° C.
The NIH 3T3 immortalized mouse fibroblast line was obtained
from the American Type Culture Collection (Rockville, MD,
USA) and was cultured in Dulbecco’s modified Eagles medium
(DMEM) with 10% fetal bovine serum (FBS, Life Technologies,
Inc., Gaithersburg, MD, USA). The AA8 and UV41 Chinese
hamster ovary cell lines were kindly provided by Dr Larry
Thompson (Lawrence Livermore National Laboratory, Livermore,
CA, USA). UV41 is a mutant cell line derived from the parental
AA8 line that is hypersensitive to DNA cross-linking agents and
defective in the ERCC4/XPF gene (Andersson et al, 1996). These
two lines were cultured in DMEM (Life Technologies, Inc.) with
10% FBS. The human non-small-lung cancer cell line, LXFL 529,
was obtained from the National Cancer Institute, NIH, and is one
of the cell lines in the panel of 60 human cell lines used to screen
for potential new anticancer compounds. This cell line was
cultured in RPMI-1640 medium with 10% FBS.
Drug exposures and clonogenic assay
For both the colony forming and alkaline elution experiments, cells
were plated in 60-mm glass dishes 1–2 days prior to the experiment
at 2 · 105–1 · 106 cells per dish. TPZ and cisplatin were made up
into solution immediately before the experiment and added to theBritish Journal of Cancer (1999) 80(8), 1245–1251cells in complete medium. Hypoxia (less than 200 ppm O2) was
achieved by exposing the glass dishes in prewarmed, air-tight
aluminium jigs to a series of five rapid evacuations and flushings
with 95% nitrogen + 5% carbon dioxide in a 37° C water bath on a
shaking platform (controls were flushed with 95% air + 5% carbon
dioxide). After the fifth evacuation and flushing, the platform (with
water bath and jigs) was shaken for 5 min, then one more evacua-
tion and flushing was performed, and the jigs were transferred to a
shaker in a 37° C incubator for the remainder of the 1-h drug expo-
sure. Levels of oxygenation between 200 ppm and air were
achieved by varying the degree and number of evacuations. The
oxygen concentrations in the medium and gas phases was checked
using an oxygen electrode (Animas, Phoenixville, PA, USA) in a
specially modified aluminium jig that allowed monitoring of both
gas and liquid phases. Following the 1 h exposure to TPZ, the
aluminium vessels were opened, the TPZ washed off the cells and
cisplatin added for 1 h in air at varying times later. At the end of the
drug treatment period the cisplatin-containing media was removed,
the cell monolayers were washed twice in medium, and either
returned to the 37° C incubator for varying times in the alkaline
elution experiments, or trypsinized, and plated for clonogenic
survival in plastic Petri dishes. The plating efficiency of all cells
used was more than 60%. Ten to 14 days later the dishes were
stained with crystal violet (0.25% in 95% ethanol) and colonies
containing more than 50 cells were counted.
Measurement of DNA interstrand cross-links by
alkaline filter elution
Alkaline elution to measure DNA single-strand breaks and DNA
interstrand cross-links was performed essentially as published
(Ewig and Kohn, 1978). Briefly, exponentially growing cells were
radiolabelled with 2-14C thymidine (0.01 m Ci ml–1) (Amersham,
Cleveland, OH, USA) for 24 h, followed by a 4-h chase period.
They were then treated with TPZ and/or cisplatin as described
above and, after an appropriate incubation period to develop and
repair cross-links, were trypsinized, resuspended in ice-cold phos-
phate-buffered saline (PBS) and half of the cells irradiated with
4 Gy at 4° C. Irradiated and/or drug-treated cells were loaded onto
a 2-m m polycarbonate filter, lysed with 2% sodium dodecyl
sulphate (SDS), 0.1 M glycine, 25 mM EDTA, pH 10.0 containing
1 mg ml–1 proteinase K (Boehringer Mannheim, Indianapolis, IN,
USA) and incubated for 1 h at room temperature. DNA was eluted
from the filter by alkaline buffer (0.1% SDS, 25 mM EDTA-free
acid, and sufficient tetrapropylammonium hydroxide to yield pH
12.2) at a flow rate of 0.033 ml min–1 for 12 h. Radioactivity from
the eluted fractions, or from the DNA retained on the filter, was
measured on a Beckman LS6000IC (Fullerton, CA, USA). Data
were analysed by plotting the log of the fraction of labelled DNA
retained on the filter versus time. The cross-link index was calcu-
lated from the ratio of the radioactivity retained on the filter after
10.5 h of elution for the radiation plus cisplatin-treated groups
divided by the corresponding radiation only group essentially as
described (Ewig and Kohn, 1978).
RESULTS
Time-dependent potentiation of cisplatin cell kill
We first measured cell killing of the combination of TPZ (1-h expo-
sure under hypoxia) with cisplatin (1-h exposure) as a function of© 1999 Cancer Research Campaign 
Mechanism of cisplatin potentiation by tirapazamine 1247
100
10–1
10–2
10–3
10–4
10–5
10–6
10–7
Su
rv
iv
in
g 
fra
ct
io
n
100
10–1
10–2
10–3
10–4
10–50 10 20 30 40 50 60 0 20 40 60
UV dose (J m–2)Cisplatin concentration (m M)
Cisplatin alone
TPZ - 0 h - Cisplatin
TPZ - 2 h - Cisplatin
UV alone
TPZ - 2 h - UV
A B
Figure 2 Clonogenic survival of NIH 3T3 cells treated with a 1-h exposure to TPZ (20 m M) combined either with cisplatin (A) or with UV irradiation (B). In panel
A the combination of TPZ with cisplatin was performed either with the two drugs given together for 1 h (TPZ – 0 h – CisPt) or with the 1-h cisplatin exposure
started 2 h after the beginning of the 1-h TPZ exposure under hypoxia (TPZ – 2 h – CisPt). In panel B the UV exposure was given either alone (2 h following the
start of a 1-h exposure of the cells under hypoxia alone), or 2 h after the start of a 1-h exposure to TPZ under hypoxia. The data show the results of single
experimentstime between the two exposures using minimally toxic doses of
each agent (less than 1 log of cell kill). As can be seen in Figure 1,
the combination of TPZ and cisplatin given at the same time under
hypoxic conditions produces approximately additive cell kill.
However, a marked potentiation of cell kill occurs when the TPZ
exposure precedes the cisplatin exposure. Note that the kinetics,
though not the magnitude, of the potentiation is similar for mouse
NIH 3T3 and the LXFL 529 human non-small-cell lung cancer cell
lines. In the groups in which cisplatin was given after the TPZ
exposure, the cisplatin dose was given under aerobic conditions.
However, we also measured survival when the cisplatin treatment© 1999 Cancer Research Campaign 
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Figure 3 Effect on clonogenic survival of combining a 1-h exposure to TPZ (18 m
(6 m M) with cisplatin (0.3 m M) on the cross-link repair-deficient cell line UV41. In bo
cisplatin was given at varying times from 1 to 4 h after the start of the 1-h TPZ exp
(means and s.e.m.)was administered under hypoxic conditions. In this case, the sensi-
tivity of the cells to either cisplatin alone or to the combination of
TPZ and cisplatin was the same as when cisplatin was administered
under aerobic conditions (data not shown). We also saw no influ-
ence on the sensitivity of the cells to cisplatin if the TPZ exposure
was under aerobic conditions (see later).
To quantitate the extent of the potentiation of cisplatin toxicity
by prior exposure of cells to TPZ under hypoxia, we measured
complete dose–response curves for cisplatin in cells treated either
2 h prior to, or concurrently with TPZ. As can be seen from Figure
2A, NIH 3T3 cells were sensitized by a dose modification factorBritish Journal of Cancer (1999) 80(8), 1245–1251
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Figure 4 (A) Alkaline filter elution profiles of NIH3T3 cells treated at 48 and 72 h after cisplatin (50 m M) either alone or 1.5 h after the start of a 1-h exposure to
TPZ (20 m M) under hypoxia. The cells treated with cisplatin alone were given a 1-h exposure to hypoxia 1.5 h before the cisplatin treatment. All groups except
the control untreated group received a radiation dose of 4 Gy on ice immediately prior to cell lysis. The groups are:(l ), control untreated cells;tt , TPZ plus
cisplatin 48 h; t , TPZ plus cisplatin 72 h; s , cisplatin alone 72 h; ss , cisplatin alone 48 h; n , TPZ alone (72 h); u , 4 Gy alone; nn , TPZ alone (48 h). Data from a
single experiment. (B) Calculated cross-link index for cells treated with cisplatin alone (n ) and those treated with TPZ 2 h before cisplatin (s ) as a function of
time after the cisplatin treatment. Pooled results of two experiments (means and s.e.m.)(DMF) of 3.5–4.0 when the TPZ and cisplatin drug exposures
were separated by 2 h compared with cells treated with TPZ and
cisplatin simultaneously.
Since at least some of the proteins involved in nuclear excision
repair (NER), a pathway involved in the repair of damage by UV
irradiation, also affect cellular sensitivity to cisplatin (Damia et al,
1996), we determined whether TPZ enhanced the sensitivity of
cells to UV irradiation. As Figure 2B shows, the combination of
UV given 2 h after a hypoxic exposure to TPZ produced only addi-
tive cell kill. This experiment suggests that the interaction with
TPZ is not directly through the NER pathway, but rather involves
a pathway that is involved specifically in the sensitivity of cells to
cisplatin.
Mechanism of the interaction
Cells deficient in DNA interstrand cross-link repair are hypersen-
sitive to killing by cisplatin and to other agents that kill cells by the
formation of DNA interstrand cross-links (Damia et al, 1996). We
therefore tested cells deficient in DNA interstrand cross-link repair
for the interaction between TPZ and cisplatin. For this we used the
hamster cell UV41, which is defective in the gene ERCC4, and
which is hypersensitive to killing by mitomycin C and to other
agents that produce DNA interstrand cross-links (Jones et al, 1990;
Andersson et al, 1996). Figure 3 shows the data for hamster UV41
cells and their wild-type counterpart, AA8 cells. As before, the
combination of TPZ with cisplatin produced additive cytotoxicity
when the two agents were given simultaneously. However, the
additional cytotoxicity produced when cisplatin followed the
hypoxic exposure to TPZ was not seen in the cross-link repair-
deficient UV41 cells, whereas it was present in the wild-type AA8
cells. These data, therefore, suggest that prior exposure of cells to
TPZ under hypoxic conditions may partially inhibit the repair of
DNA cross-links. One caveat to these data, however, is that inBritish Journal of Cancer (1999) 80(8), 1245–1251order to have comparable cell survival of the UV41 and AA8 cells
to cisplatin and TPZ alone, it was necessary to give much lower
doses of the two drugs with the UV41 cells (60-fold lower for
cisplatin and threefold lower for TPZ compared to the doses used
for the AA8 cells).
To more directly test the effect of TPZ on interstrand cross-links,
we next measured DNA interstrand cross-links, using alkaline filter
elution, following cisplatin exposure with or without prior treat-
ment to TPZ under hypoxia. In these experiments, NIH 3T3 cells
were treated with cisplatin (50 m M for 1 h) either alone, or 30 min
after the end of a 1-h exposure to TPZ (20 m M under hypoxia). The
cells treated with cisplatin alone were given a 1-h treatment of
hypoxia starting 1.5 h prior to the cisplatin exposure. Figure 4
shows the alkaline elution data at 48 and 72 h after the cisplatin
treatment, and the calculation of the DNA interstrand cross-link
factor from 0 to 72 h following cisplatin exposure. The data show
that the initial level of DNA interstrand cross-links is similar for the
two groups, but the cells treated with TPZ under hypoxia prior to
cisplatin have less repair of the cross-links after the peak at approx-
imately 12 h after exposure compared with cells treated with
cisplatin alone. The area under the curve of cross-links as a func-
tion of time (which has been shown to correlate with cytotoxicity;
Hansson et al, 1987) for the TPZ + cisplatin group is 2.8 times
greater than that for the cisplatin only group. This is to be compared
with a DMF of 3.5–4.0 for cell killing (Figure 2). Considering
interexperimental variability and the very different nature of the
assays involved, these data support the conclusion that most, if not
all, of the potentiation of cisplatin cell kill by TPZ can be accounted
for by an increased incidence of DNA interstrand cross-links.
Oxygen dependence of cisplatin sensitization by TPZ
In all of the experiments described above, the TPZ exposure was
given under conditions of extreme hypoxia (approximately 0.02%© 1999 Cancer Research Campaign 
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Figure 5 The effect of varying oxygen concentrations on the cytotoxicity of
NIH 3T3 cells treated with TPZ (1.5 h) alone (25 m M), with cisplatin alone
(20 m M), or with TPZ followed 2 h later with cisplatin. The data are pooled
from two experiments. Also shown is the range of oxygen concentrations
typical of normal tissues and of tumoursoxygen measured in the medium). In many control experiments
(data not shown), we found no interaction when the TPZ was given
under aerobic conditions (20% oxygen). Since the median oxygen
concentration in tumours spans a wide range from approximately
0.1 to 4% (Lartigau et al, 1993; Nordsmark et al, 1994; Vaupel
and Hockel, 1995), we tested the interaction between TPZ and
cisplatin as a function of oxygen concentration. In this experiment,
NIH 3T3 cells were exposed under varying oxygen concentrations
for 1.5 h either to 25 m M TPZ or to a combination of TPZ with
20 m M cisplatin started 1 h after the end of the TPZ exposure. The
results (Figure 5) show that the interaction between the two drugs
starts to occur at oxygen concentrations less than 1% and before
there is any cytotoxicity by the TPZ alone. At very low oxygen
concentrations, the additional cell kill produced by the combina-
tion of TPZ and cisplatin over that of cisplatin alone is a result both
of cell killing by TPZ and of the interaction between the two drugs.
Also shown on Figure 5 are the typical ranges of oxygen concen-
trations of cells in tumours and subcutaneous normal tissues.
DISCUSSION
The purpose of the present study was to investigate the mechanism
by which TPZ potentiates the cytotoxicity of cisplatin. We have
previously shown that there is a tumour-specific synergistic interac-
tion between these two agents in transplanted mouse tumours when
TPZ is given prior to, but not at the same time as, cisplatin (Dorie
and Brown, 1993). Although an interaction between TPZ and other
anticancer drugs has been reported (Langmuir et al, 1994; Siemann,
1996; Dorie and Brown, 1997), none is as dramatic as with plat-
inum-containing drugs and may result from complementary cyto-
toxicity within the tumour and/or may not lead to a therapeutic gain
(Siemann, 1996). The tumour specificity of the interaction between
TPZ and cisplatin has led to clinical trials of the combination of the
two drugs, which have shown that TPZ can produce a therapeutic
gain by potentiating the anti-tumour efficacy of cisplatin without
changing its systemic toxicity (Treat et al, 1998; von Pawel and von
Roemeling, 1998). Our experiments in the present study show that
the interaction between the two drugs depends on the TPZ exposure© 1999 Cancer Research Campaign being under oxygen concentrations of less than 1%, and that it can
be demonstrated at the cellular level. The fact that the characteris-
tics and timing of the interaction (i.e. additive when the two drugs
are given simultaneously, but synergistic when TPZ precedes
cisplatin) are similar for both the in vitro and in vivo exposures
suggests that most, if not all, of the in vivo synergy is the conse-
quence of a cellular interaction between the two drugs. This was by
no means obvious since it has been shown by several investigators
that hypoxic cells in tumours are preferentially spared from
cisplatin cell kill (Grau and Overgaard, 1988), and complementary
cytotoxicity between TPZ and cisplatin could have produced an
apparently synergistic interaction. However, complementary cell
kill could still account for part of the interaction in vivo, depending
on the dose of TPZ administered and the sensitivity of the tumour
cells to TPZ-induced cell kill. It could also be responsible for the
(lesser) interaction between TPZ and other anticancer drugs (Dorie
and Brown, 1997).
Our data on the oxygen dependence of the interaction between
the two drugs can account for the tumour specificity of cisplatin
potentiation by TPZ. We show (Figure 5) that at oxygen concen-
trations typical of normal tissues, there is no interaction between
TPZ and cisplatin, whereas at lower oxygen concentrations, which
occur commonly in tumours, TPZ potentiates the cytotoxicity of
cisplatin. It seems reasonable, therefore, to conclude that the
tumour specific potentiation of cisplatin cytotoxicity seen in both
preclinical and clinical studies is the result of the lower oxygen
levels present in solid tumours. The presence of such hypoxic
regions has been demonstrated in all human solid tumours so far
studied, including brain (Cruickshank et al, 1994), head and neck
(Nordsmark et al, 1994; Adam et al, 1998), lung (Urtasun et al,
1986), breast (Vaupel et al, 1991), cervix (Hockel et al, 1991),
melanoma (Lartigau et al, 1997), anal canal (Mattern et al, 1996)
and soft tissue sarcomas (Brizel et al, 1994). All of these data show
that the median oxygen concentration of human solid tumours is
highly heterogeneous, but that the vast majority of tumours have
median oxygen levels lower than those of normal tissues.
It should also be pointed out that the present data demonstrate a
significant potentiation of cisplatin cytotoxicity at oxygen levels
considerably higher than those normally associated with the
‘hypoxic fraction’ of tumours, which usually means cells at
maximum radiation resistance, or below 0.1–0.2% oxygen (Koch
et al, 1984). It has previously been shown that TPZ has a different
oxygen dependency for cytotoxicity compared to other bioreduc-
tive drugs of the nitroimidazole or quinone antibiotic class in that
it produces cytotoxicity at higher oxygen concentrations (Koch,
1993). We show here that significant potentiation of cisplatin cyto-
toxicity occurs at oxygen concentrations at which TPZ alone is not
cytotoxic (Figure 5). It seems reasonable, therefore, to suppose
that in many tumours most, if not all, of the cells may be sensitized
to cisplatin cell kill by TPZ. Indeed, in elegant studies of oxygen
levels in human tumour xenografts, Helmlinger and colleagues
(Helmlinger et al, 1997) showed that the mean oxygen level adja-
cent to capillaries is 15 mmHg, or approximately 2% oxygen.
Given our data showing cisplatin potentiation by TPZ beginning at
1–2% oxygen (Figure 5), this could readily account for the
published data showing potentiation of cisplatin cytotoxicity by
TPZ in all the cells of xenografted human tumours, including those
closest to the blood vessels (Durand, 1994).
The present data provide further insight into the mechanism by
which hypoxic exposure to TPZ potentiates cisplatin cytotoxicity.
First, we show that this interaction is absent in CHO UV41 cells,British Journal of Cancer (1999) 80(8), 1245–1251
1250 MS Kovacs et alwhich are deficient in the ERCC4 protein and in the repair of DNA
interstrand cross-links (Andersson et al, 1996). These data impli-
cate ERCC4, or its partner ERCC1, or other proteins involved in
the repair of DNA interstrand cross-links, as involved in the mech-
anism of the potentiation. We obtained direct evidence for this by
measuring DNA interstrand cross-links in cells following cisplatin
treatment with or without prior exposure to TPZ under hypoxia.
The fact that we saw similar levels of initial DNA cross-links,
but higher levels following a repair period suggests that TPZ
exposure either inhibits cross-link repair or the repair of cisplatin
monoadducts prior to their formation of interstrand cross-links.
At present we can only speculate on the possible mechanism by
which TPZ could inhibit the repair of DNA interstrand cross-links
produced by cisplatin. However, our recent finding that all of the
DNA damage produced by TPZ occurs by metabolism of the drug
within the nucleus (Evans et al, 1998), and that protein fractions
associated with the nuclear matrix are highly active in TPZ metab-
olism (Delahoussaye et al, 1997), suggests that TPZ damage could
be preferentially localized to DNA closely associated with the
nuclear matrix. Since the nuclear matrix is the site for DNA repli-
cation (Berezney and Coffey, 1975) and transcription (Cook, 1989),
TPZ damage could have an effect on these processes. We have in
fact observed a large inhibition of both DNA replication and
transcription by TPZ even at minimally cytotoxic concentrations
(KB Peters et al, unpublished observations). We suggest therefore
that sensitization of cells to cisplatin could be the result of an inhi-
bition by TPZ of transcription of genes involved in the repair of
DNA cross-links following cisplatin exposure. In this regard it has
recently been reported that cisplatin exposure of ovarian cancer
cells increases transcription and protein levels of ERCC1 (Li et al,
1998). As message levels of this gene have been reported to corre-
late with cisplatin sensitivity (Dabholkar et al, 1992), it seems
reasonable to speculate that inhibition by TPZ of enhanced tran-
scription of ERCC1 would sensitize the cells to cisplatin cytotoxi-
city. Experiments to test this hypothesis are currently underway.
In conclusion, we show that the tumour-specific potentiation of
cisplatin cell kill by TPZ can be accounted for by a cellular inter-
action between the two drugs that appears to involve a diminished,
or delayed, repair of cisplatin-induced interstrand cross-links. We
further show that this interaction can occur at non-toxic concentra-
tions of TPZ, but requires the TPZ exposure to be under oxygen
concentrations lower than are those of normal tissues, but typical
of those in solid tumours. These data provide mechanistic insight
into the preclinical and clinical data showing that TPZ can produce
a therapeutic gain when added to cisplatin in the treatment of solid
tumours.
ACKNOWLEDGEMENTS
This work was supported by USPHS grant CA 67166 (to JMB),
and by a National Cancer Institute of Canada Junior Research
Fellowship #6453 (to BGW).
REFERENCES
Adam M, Gabalski EC, Oehlert JW, Bloch DA, Brown JM, Elsaid AA, Pinto HA
and Terris DJ (1999) Tissue oxygen distribution in head and neck patients.
Head Neck 21: 146–153
Andersson BS, Sadeghi T, Siciliano MJ, Legerski R and Murray D (1996)
Nucleotide excision repair genes as determinants of cellular sensitivity to
cyclophosphamide analogs. Cancer Chemother Pharmacol 38: 406–416British Journal of Cancer (1999) 80(8), 1245–1251Berezney R and Coffey DS (1975) Nuclear protein matrix: association with newly
synthesized DNA. Science 189: 291–293
Brizel DM, Rosner GL, Harrelson J, Prosnitz LR and Dewhirst MW (1994)
Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat
Oncol Biol Phys 30: 635–642
Brizel DM, Sibley GS, Prosnitz LR, Scher RL and Dewhirst MW (1997) Tumor
hypoxia adversely affects the prognosis of carcinoma of the head and neck.
Int I Radiat Oncol Biol Phys 38: 285–289
Brown JM (1993) SR 4233 (tirapazamine): a new anticancer drug exploiting
hypoxia in solid tumours. Br J Cancer 67: 1163–1170
Brown JM and Lemmon MJ (1990) Potentiation by the hypoxic cytotoxin SR 4233
of cell killing produced by fractionated irradiation of mouse tumors. Cancer
Res 50: 7745–7749
Brown JM and Lemmon MJ (1991) Tumor hypoxia can be exploited to
preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol
Biol Phys 20: 457–461
Cook PR (1989) The nucleoskeleton and the topology of transcription. Eur J
Biochem 185: 487–501
Cruickshank GS, Rampling RP and Cowans W (1994) Direct measurement of the
PO2 distribution in human malignant brain tumours. Adv Exp Med Biol 345:
465–470
Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C and Reed E (1992)
ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer
patients. J Natl Cancer Inst 84: 1512–1517
Damia G, Imperatori L, Stefanini M and D’Incalci M (1996) Sensitivity of CHO
mutant cell lines with specific defects in nucleotide excision repair to different
anti-cancer agents. Int J Cancer 66: 779–783
Delahoussaye YM, Wouters BG, Evans JE and Brown JM (1997) Intranuclear
metabolism of tirapazamine by matrix-associated reductases. Proc Am Assoc
Cancer Res 38: 163 (abstr. # 1095)
Dorie MJ and Brown JM (1993) Tumor-specific, schedule-dependent
interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53:
4633–4636
Dorie MJ and Brown JM (1997) Modification of the antitumor activity of
chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer
Chemother Pharmacol 39: 361–366
Durand RE (1994) The influence of microenvironmental factors during cancer
therapy. In vivo 8: 691–702
Evans JE, Yudoh K, Delahoussaye YM and Brown JM (1998) Tirapazamine is
metabolized to its DNA damaging radical by intranuclear enzymes. Cancer Res
58: 2098–2101
Ewig RA and Kohn KW (1978) DNA-protein cross-linking and DNA interstrand
cross-linking by haloethylnitrosoureas in L1210 cells. Cancer Res 38:
3197–3203
Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ and Hartz WH
(1988) Oxygen distribution in squamous cell carcinoma metastases and its
relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14:
831–838
Graham MA, Senan S, Robin H, Eckhardt N, Lendrem D, Hincks J, Greenslade D,
Rampling R, Kaye SB, von Roemeling R and Workman P (1997)
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its
major bioreductive metabolites in mice and humans: retrospective analysis of a
pharmacokinetically guided dose escalation strategy in a phase I trial. Cancer
Chemother Pharmacokin 40: 1–10
Grau C and Overgaard J (1988) Effect of cancer chemotherapy on the hypoxic
fraction of a solid tumor measured using a local tumor control assay. Radiother
Oncol 13: 301–309
Hansson J, Lewensohn R, Ringborg U and Nilsson B (1987) Formation and removal
of DNA cross-links induced by melphalan and nitrogen mustard in relation to
drug-induced cytotoxicity in human melanoma cells. Cancer Res 47:
2631–2637
Helmlinger G, Yuan F, Dellian M and Jain RK (1997) Interstitial pH and pO2
gradients in solid tumors in vivo: high-resolution measurements reveal a lack
of correlation. Nat Med 3: 177–182
Hockel M, Schlenger K, Knoop C and Vaupel P (1991) Oxygenation of carcinomas
of the uterine cervix: evaluation by computerized O2 tension measurements.
Cancer Res 51: 6098–6102
Jones NJ, Stewart SA and Thompson LH (1990) Biochemical and genetic analysis
of the Chinese hamster mutants irs1 and irs2 and their comparison to cultured
ataxia telangiectasia cells. Mutagenesis 5: 15–23
Kim IH and Brown JM (1994) Reoxygenation and rehypoxiation in the SCCVII
mouse tumor. Int J Radiat Oncol Biol Phys 29: 493–497
Koch CJ (1993) Unusual oxygen concentration dependence of toxicity of SR-4233, a
hypoxic cell toxin. Cancer Res 53: 3992–3997© 1999 Cancer Research Campaign 
Mechanism of cisplatin potentiation by tirapazamine 1251Miller VA, Ng KK, Grant SC, Kindler H, Pizzo B, Heelan RT, von Roemeling R and
Kris MG (1997) Phase II study of the combination of the novel bioreductive
agent, tirapazamine, with cisplatin in patients with advanced non-small-cell
lung cancer. Ann Oncol 8: 1269–1271
Nordsmark M, Bentzen SM and Overgaard J (1994) Measurement of human tumour
oxygenation status by a polarographic needle electrode. Acta Oncol 33:
383–389
Nordsmark M, Overgaard M and Overgaard J (1996) Pretreatment oxygenation
predicts radiation response in advanced squamous cell carcinoma of the head
and neck. Radiother Oncol 41: 31–40
Rodriguez GI, Valdivieso M, Von Hoff DD, Kraut M, Burris HA, Eckardt JR,
Lockwood G, Kennedy H and von Roemeling R (1996) A phase I/II trial of the
combination of tirapazamine and cisplatin in patients with non-small cell lung
cancer (NSCLC). Proc Am Soc Clin Oncol 15: 382 (abstract)
Siemann DW (1996) The in situ tumour response to combinations of
cyclophosphamide and tirapazamine. Br J Cancer 74: S65–69
Siemann DW and Hinchman CA (1998) Potentiation of cisplatin activity by the
bioreductive agent tirapazamine. Radiother Oncol 47: 215–220
Treat J, Haynes B, Johnson E, Belani C, Greenberg R, Rodriquez R, Drobbins P,
Miller WJ, Meehan L and von Roemeling R (1997) Tirapazamine with
cisplatin: a phase II trial in advanced stage non-small cell lung cancer
(NSCLC). Proc Am Soc Clin Oncol 16: 1633 (abstract)© 1999 Cancer Research Campaign Treat J, Johnson E, Langer C, Belani C, Haynes B, Greenberg R, Rodriquez R,
Drobins P, Miller W, Jr Meehan L, McKeon A, Devin J, von Roemeling R and
Viallet J (1998) Tirapazamine with cisplatin in patients with advanced non-
small-cell lung cancer: a phase II study. J Clin Oncol 16: 3524–3527
Urtasun RC, Chapman JD, Raleigh JA, Franko AJ and Koch CJ (1986) Binding of
3H-misonidazole to solid human tumors as a measure of tumor hypoxia. Int J
Radiat Oncol Biol Phys 12: 1263–1267
Vaupel PW and Hockel M (1995) Oxygenation status of human tumors: a reappraisal
using computerized pO2 histography. In Tumor Oxygenation, Vaupel PW,
Kelleher DK and Gunderoth M (ed) pp. 219–232. Gustav Fischer Verlag:
Stuttgart
Vaupel PW, Schlenger K, Knoop C and Hockel M (1991) Oxygenation of human
tumors: evaluation of tissue oxygen distribution in breast cancers by
computerized O2 tension measurements. Cancer Res 51: 3316–3322
von Pawel J and von Roemeling R (1998) Survival benefit from tirazone
(tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC)
patients: final results from the international phase III CATAPULT 1 trial. Proc
Am Soc Clin Oncol 17: 454a (Abstract)
Zeman EM, Brown JM, Lemmon MJ, Hirst VK and Lee WW (1986) SR-4233: a
new bioreductive agent with high selective toxicity for hypoxic mammalian
cells. Int J Radiat Oncol Biol Phys 12: 1239–1242British Journal of Cancer (1999) 80(8), 1245–1251
